Cell Reports (Sep 2015)

Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression

  • Janneke G.C. Peeters,
  • Stephin J. Vervoort,
  • Sander C. Tan,
  • Gerdien Mijnheer,
  • Sytze de Roock,
  • Sebastiaan J. Vastert,
  • Edward E.S. Nieuwenhuis,
  • Femke van Wijk,
  • Berent J. Prakken,
  • Menno P. Creyghton,
  • Paul J. Coffer,
  • Michal Mokry,
  • Jorg van Loosdregt

DOI
https://doi.org/10.1016/j.celrep.2015.08.046
Journal volume & issue
Vol. 12, no. 12
pp. 1986 – 1996

Abstract

Read online

The underlying molecular mechanisms for many autoimmune diseases are poorly understood. Juvenile idiopathic arthritis (JIA) is an exceptionally well-suited model for studying autoimmune diseases due to its early onset and the possibility to analyze cells derived from the site of inflammation. Epigenetic profiling, utilizing primary JIA patient-derived cells, can contribute to the understanding of autoimmune diseases. With H3K27ac chromatin immunoprecipitation, we identified a disease-specific, inflammation-associated, typical enhancer and super-enhancer signature in JIA patient synovial-fluid-derived CD4+ memory/effector T cells. RNA sequencing of autoinflammatory site-derived patient T cells revealed that BET inhibition, utilizing JQ1, inhibited immune-related super-enhancers and preferentially reduced disease-associated gene expression, including cytokine-related processes. Altogether, these results demonstrate the potential use of enhancer profiling to identify disease mediators and provide evidence for BET inhibition as a possible therapeutic approach for the treatment of autoimmune diseases.